Da Pang

机构：System Equipment (China) · ORCID：0000-0003-2853-4170

发表论文 267 篇 · 总被引 7739 次 · h-index 49

代表论文

• Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer (2024 · JAMA · 被引 47)
• FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A/YTHDF3/PDK1 axis under hypoxic conditions (2024 · Journal of Advanced Research · 被引 37)
• Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial (2024 · Nature Communications · 被引 32)
• The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity (2025 · Drug Resistance Updates · 被引 27)
• H4K79 and H4K91 histone lactylation, newly identified lactylation sites enriched in breast cancer (2025 · Journal of Experimental & Clinical Cancer Research · 被引 18)
• Desmocollin 2 is a dominant entry receptor for Epstein–Barr virus infection of epithelial cells (2025 · Nature Microbiology · 被引 14)